Bridgeway Capital Management’s Astria Therapeutics ATXS Stock Holding History

Bridgeway Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,101	Closed	-$331K	–	1207
2024 Q3	$331K	Hold	30,101	–	–	0.01%	956
2024 Q2	$274K	Sell	30,101 -5,000	-14%	-$48.8K	0.01%	985
2024 Q1	$494K	Sell	35,101 -61,200	-64%	-$762K	0.01%	934
2023 Q4	$740K	Buy	96,301 +31,100	+48%	+$172K	0.02%	836
2023 Q3	$486K	Buy	65,201 +30,201	+86%	+$258K	0.01%	876
2023 Q2	$292K	Hold	35,000	–	–	0.01%	1052
2023 Q1	$466K	Hold	35,000	–	–	0.01%	907
2022 Q4	$521K	Hold	35,000	–	–	0.01%	873
2022 Q3	$316K	Sell	35,000 -79,279	-69%	-$531K	0.01%	1018
2022 Q2	$343K	Buy	114,279 +50,000	+78%	+$224K	0.01%	965
2022 Q1	$431K	Buy	64,279 +19,279	+43%	+$115K	0.01%	975
2021 Q4	$243K	Buy	+45,000	New	+$296K	﹤0.01%	1135
2021 Q2	–	Sell	-17,933	Closed	-$311K	–	1334
2021 Q1	$311K	Buy	17,933 +15,850	+761%	+$286K	0.01%	1217
2020 Q4	$27K	Sell	2,083 -12,967	-86%	-$231K	﹤0.01%	1299
2020 Q3	$559K	Hold	15,050	–	–	0.01%	846
2020 Q2	$581K	Buy	15,050 +5,883	+64%	+$210K	0.01%	807
2020 Q1	$228K	Buy	+9,167	New	+$284K	0.01%	1019
2019 Q4	–	Sell	-3,483	Closed	-$113K	–	1314
2019 Q3	$113K	Hold	3,483	–	–	﹤0.01%	1236
2019 Q2	$169K	Buy	+3,483	New	+$158K	﹤0.01%	1201
2018 Q4	–	Sell	-1,505	Closed	-$72K	–	1373
2018 Q3	$72K	Hold	1,505	–	–	﹤0.01%	1398
2018 Q2	$87K	Buy	+1,505	New	+$139K	﹤0.01%	1371
2017 Q2	–	Sell	-1,689	Closed	-$162K	–	1418
2017 Q1	$162K	Hold	1,689	–	–	﹤0.01%	1304
2016 Q4	$366K	Buy	1,689 +833	+97%	+$204K	﹤0.01%	1182
2016 Q3	$316K	Buy	856 +394	+85%	+$104K	﹤0.01%	1230
2016 Q2	$102K	Buy	+462	New	+$139K	﹤0.01%	1381

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bridgeway Capital Management's ATXS Position: Q4 2024 in Review

Bridgeway Capital Management sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 30,101 shares — an estimated $331K sold.

Bridgeway Capital Management first reported a position in ATXS in Q2 2016 and held it in 25 quarters. The position peaked at $740K in Q4 2023. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

Bridgeway Capital Management reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
Bridgeway Capital Management sold 30,101 Astria Therapeutics shares in Q4 2024, an estimated $331K.
Bridgeway Capital Management first reported a position in Astria Therapeutics in Q2 2016 and held it in 25 quarters.
Bridgeway Capital Management's Astria Therapeutics position peaked at $740K in Q4 2023.
110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Bridgeway Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.